Cara Therapeutics
CARA
#9655
Rank
C$25.11 M
Marketcap
$0.46
Share price
0.77%
Change (1 day)
-71.88%
Change (1 year)

P/E ratio for Cara Therapeutics (CARA)

P/E ratio as of November 2024 (TTM): -0.1573

According to Cara Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.15733. At the end of 2022 the company had a P/E ratio of -6.75.

P/E ratio history for Cara Therapeutics from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-6.75-4.06%
2021-7.04-108.38%
202084.1-1399.18%
2019-6.472.52%
2018-6.31-1.52%
2017-6.4144.86%
2016-4.42-73.76%
2015-16.943.74%
2014-11.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.3795 141.19%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
-2.79 1,671.23%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.2783 76.90%๐Ÿ‡บ๐Ÿ‡ธ USA
14.4-9,230.87%๐Ÿ‡บ๐Ÿ‡ธ USA
10.9-7,015.02%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0676-57.03%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.